These mutations are rarely found in primary estrogen receptor-positive (ER + ) breast cancers but have a high prevalence in metastatic disease and lead to constitutive ligand independent activity.1–3 The most prevalent mutations as detected in a number of studies are the Y537S and D538G mutations. Here, ESR1 is linked to breast carcinoma.